CTLA4 and glioblastoma: For example, targeting CD73hi macrophages via depletion of CD73 in CD73−/− mice extends the survival of GBM-bearing mice, and this effect is further improved when combined with anti–PD-1 and anti-CTLA4 therapies (62).